{
    "ticker": "NRIX",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage immunotherapy company dedicated to harnessing the power of the immune system to treat various forms of cancer and infectious diseases. Founded in 2015 by Dr. Patrick Soon-Shiong, NantKwest focuses on developing innovative therapies that leverage natural killer (NK) cells, a type of immune cell known for its ability to detect and eliminate tumors and virally infected cells. The company\u2019s lead product candidate, an off-the-shelf NK cell therapy, is designed to provide a novel approach to cancer treatment by enhancing the body\u2019s innate immune response. NantKwest is also advancing a pipeline of other therapies that include engineered NK cells and various combination treatments aimed at maximizing therapeutic efficacy. With a commitment to translating scientific discoveries into clinical applications, NantKwest collaborates with leading research institutions and hospitals to conduct rigorous clinical trials. The company strives to improve patient outcomes in oncology and infectious disease by developing transformative therapies that can potentially change the standard of care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Culver City, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "Dr. Patrick Soon-Shiong",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://investors.nantkwest.com",
    "key_executives": [
        {
            "name": "Dr. Patrick Soon-Shiong",
            "position": "CEO"
        },
        {
            "name": "Dr. James M. E. Wong",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "Off-the-Shelf NK Cell Therapy"
            ]
        },
        {
            "category": "Combination Therapies",
            "products": [
                "Engineered NK Cells"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Learn about NantKwest, Inc., a leader in immunotherapy focused on developing NK cell therapies for cancer treatment. Discover their innovative approach and clinical pipeline.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "NK Cells",
            "Cancer Treatment",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is NantKwest known for?",
            "answer": "NantKwest is known for its innovative immunotherapy solutions leveraging natural killer (NK) cells to treat cancer and infectious diseases."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "Dr. Patrick Soon-Shiong is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Culver City, California, USA."
        },
        {
            "question": "What are NantKwest's main products?",
            "answer": "NantKwest's main products include off-the-shelf NK cell therapies and engineered NK cell therapies."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "NK",
        "CARA",
        "ZIOP",
        "IMAB"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "VRTX"
    ]
}